US equities |
GOOGL $283.13 ▼-12.85% GOOG $281.32 ▼-12.60% MSFT $529.54 ▼-0.28% MU $943.68 ▼-4.02% AMZN $244.85 ▼-3.83% NVDA $212.54 ▼-1.32% META $621.72 ▲+1.51% AAPL $349.00 ▲+1.50%
FinancialContent

Kairos Pharma, Ltd. Common Stock (NY:KAPA)

0.5520 +0.0289 (+5.52%)
Delayed Quote Updated: 9:36 AM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kairos Pharma, Ltd. Common Stock

< Previous 1 2 3 4 5 6 Next >
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Earns 2026 Pinnacle Award for Biotech Innovation in Cancer Drug Resistance
Via Investor Brand Network
News headline image
Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
From Rosen Law Firm, P.A.
Via Business Wire
News headline image
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA
From The Rosen Law Firm, P.A.
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Enters Binding Terms To Acquire CL-273 For EGFR-Mutant Lung Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
BioMedNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Signs Term Sheet to Acquire Two Clinical-Stage NSCLC Assets
Via Investor Brand Network
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
From Kairos Pharma, Ltd
Via Business Wire
TinyGemsBreaks – To Participate In DealFlow Discovery Conference
Via Investor Brand Network
News headline image
Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2025 Milestones and Clinical Progress in CEO Letter to Shareholders
Via Investor Brand Network
News headline image
Kairos Pharma Provides Shareholder Update
From Kairos Pharma Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Results for ENV-105 in Advanced Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting
From Kairos Pharma, Ltd
Via Business Wire
News headline image
Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
From Kairos Pharma, Ltd
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Top movers in Friday's session ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Interim Phase 2 Data for ENV105 in Prostate Cancer
Via Investor Brand Network
News headline image
Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Host KOL Event on Phase 2 ENV105 Prostate Cancer Trial
Via Investor Brand Network
News headline image
Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >